Cadrenal Therapeutics Inc
CVKD
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.89M
Close$
$2.01
89.6% upside
Current Fair Value
89.6% upsideUndervalued by 89.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.89 Million |
|---|---|
| Enterprise Value | $1.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.64 |
| Beta | 1.84 |
| Outstanding Shares | 2,913,225 |
Return
| Return on Equity | -221.11% |
|---|---|
| Return on Assets | -161.88% |
| Return on Invested Capital | -283.65% |
Valuation & Multiples
| P/E Ratio | -0.22 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.06 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.13 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.42
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.86%▲ 0.08% |
|---|---|
| Total Invested | $375,540▼ 18.26% |
| Investors Holding | 170% |
ESG Score
No data